Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, observational study comparing clinical outcomes of adults with T2D switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)

Trial Profile

A retrospective, observational study comparing clinical outcomes of adults with T2D switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2018

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DELIVER D+
  • Most Recent Events

    • 20 Jul 2018 New trial record
    • 26 Jun 2018 Results from subgroups of this trial presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top